{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T01:00:38Z","timestamp":1770512438253,"version":"3.49.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T00:00:00Z","timestamp":1505692800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s11926-017-0691-3","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T03:35:07Z","timestamp":1505705707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Duality of Economic Issues With Medication Non-adherence in Patients With Inflammatory Arthritis"],"prefix":"10.1007","volume":"19","author":[{"given":"Natasha K. J.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Saadeldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary A.","family":"De Vera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,18]]},"reference":[{"issue":"10","key":"691_CR1","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/acr.22336","volume":"66","author":"MA Vera De","year":"2014","unstructured":"\u2022 De Vera MA, Marcotte G, Rai S, et al. Medication adherence in gout: a systematic review. Arthritis Care Res. 2014;66(10):1551\u20139. This systematic review synthesized empirical evidence on the burden, predictors, and impacts of non-adherence in gout.","journal-title":"Arthritis Care Res"},{"key":"691_CR2","doi-asserted-by":"crossref","unstructured":"\u2022 Mehat P, Atiquzzaman M, Esdaile JM, et al. Medication non-adherence in systemic lupus erythematosus: a systematic review. Arthritis Care & Research. 2017 (published online 13 January 2017). This systematic review synthesized the data on the burden and determinants of medication non-adherence among SLE patients.","DOI":"10.1002\/acr.23191"},{"issue":"4","key":"691_CR3","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/NOR.0b013e3181e5c2c9","volume":"29","author":"E Salt","year":"2010","unstructured":"Salt E, Frazier S. Adherence to disease modifying anti-rheumatic drugs in rheumatoid arthritis patients: a narrative review of the literature. Orthop Nurs. 2010;29(4):260\u201375.","journal-title":"Orthop Nurs"},{"issue":"1","key":"691_CR4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semarthrit.2012.12.001","volume":"43","author":"A Pasma","year":"2013","unstructured":"Pasma A, van\u2019t Spijker A, Hazes JM, et al. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review. Semin Arthritis Rheum. 2013;43(1):18\u201328.","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"691_CR5","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s11926-014-0460-5","volume":"16","author":"MA Vera De","year":"2014","unstructured":"De Vera MA, Mailman J, Galo JS. Economics of non-adherence to biologic therapies in rheumatoid arthritis. Curr Rheumatol Rep. 2014;16(11):460.","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"691_CR6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1586\/eci.12.23","volume":"8","author":"BJ Bemt van den","year":"2012","unstructured":"van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol. 2012;8(4):337\u201351.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"691_CR7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2217\/ijr.15.39","volume":"10","author":"MF Marengo","year":"2015","unstructured":"\u2022 Marengo MF, Suarez-Almazor ME. Improving treatment adherence in patients with rheumatoid arthritis: what are the options? Int J Clin Rheumatol. 2015;10(5):345\u201356. This review summarized the recent literature on determinants of adherence, and related interventions, that can improve therapeutic adherence in patients with RA.","journal-title":"Int J Clin Rheumatol"},{"issue":"12","key":"691_CR8","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/acr.22636","volume":"67","author":"CH Feldman","year":"2015","unstructured":"Feldman CH, Yazdany J, Guan H, et al. Medication nonadherence is associated with increased subsequent acute care utilization among Medicaid beneficiaries with systemic lupus erythematosus. Arthritis Care Res. 2015;67(12):1712\u201321.","journal-title":"Arthritis Care Res"},{"issue":"2","key":"691_CR9","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/art.24236","volume":"61","author":"LJ Julian","year":"2009","unstructured":"Julian LJ, Yelin E, Yazdany J, et al. Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Care Res. 2009;61(2):240\u20136.","journal-title":"Arthritis Care Res"},{"issue":"7","key":"691_CR10","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1185\/03007990903017966","volume":"25","author":"R Halpern","year":"2009","unstructured":"Halpern R, Mody RR, Fuldeore MJ, et al. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin. 2009;25(7):1711\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"691_CR11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/MAJ.0b013e3181e8bcb0","volume":"340","author":"I Contreras-Y\u00e1\u00f1ez","year":"2010","unstructured":"Contreras-Y\u00e1\u00f1ez I, Cabiedes J, Rull-Gabayet M, et al. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am J Med Sci. 2010;340(4):282\u201390.","journal-title":"Am J Med Sci"},{"key":"691_CR12","unstructured":"Sabate E. Adherence to long-term therapies: evidence for action. Geneva, Switzerland: World Health Organization; 2003."},{"key":"691_CR13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fphar.2013.00091","volume":"4","author":"P Kardas","year":"2013","unstructured":"Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol. 2013;4:91.","journal-title":"Front Pharmacol"},{"key":"691_CR14","first-page":"35","volume":"7","author":"AO Iuga","year":"2014","unstructured":"Iuga AO, McGuire MJ. Adherence and health care costs. Risk Manag & Healthcare Policy. 2014;7:35\u201344.","journal-title":"Risk Manag & Healthcare Policy"},{"issue":"1","key":"691_CR15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44\u20137.","journal-title":"Value Health"},{"issue":"7\u20138","key":"691_CR16","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1345\/aph.1H018","volume":"40","author":"LM Hess","year":"2006","unstructured":"Hess LM, Raebel MA, Conner DA, et al. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40(7\u20138):1280\u20138.","journal-title":"Ann Pharmacother"},{"issue":"5","key":"691_CR17","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","volume":"73","author":"B Vrijens","year":"2012","unstructured":"Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691\u2013705.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"691_CR18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487\u201397.","journal-title":"N Engl J Med"},{"issue":"5","key":"691_CR19","first-page":"103","volume":"11","author":"JV Urquhart","year":"2005","unstructured":"Urquhart JV, B. New findings about ptaient adherence to prescribed drug dosing regimens: an introduction to pharmionics. Eur J Hospital Phar Sci. 2005;11(5):103\u20136.","journal-title":"Eur J Hospital Phar Sci"},{"issue":"9","key":"691_CR20","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/rheumatology\/kel245","volume":"45","author":"D Mulherin","year":"2006","unstructured":"Mulherin D, Wong M. Drug survival in rheumatoid arthritis. Rheumatology. 2006;45(9):1178. author reply -9","journal-title":"Rheumatology"},{"issue":"9","key":"691_CR21","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1517\/14712598.2010.510508","volume":"10","author":"T Koncz","year":"2010","unstructured":"Koncz T, Pentek M, Brodszky V, et al. Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opin Biol Ther. 2010;10(9):1367\u201378.","journal-title":"Expert Opin Biol Ther"},{"key":"691_CR22","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/rheumatology\/kel246","volume":"45","author":"GL Treharne","year":"2006","unstructured":"Treharne GL, Hale A, et al. Drug survival in rheumatoid arthritis\u2014an interesting method but not a measure of adherence or corcodance. Rheumatology. 2006;45:1178\u20139.","journal-title":"Rheumatology"},{"key":"691_CR23","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2147\/PPA.S47453","volume":"7","author":"V Martinez-Santana","year":"2013","unstructured":"Martinez-Santana V, Gonzalez-Sarmiento E, Calleja-Hernandez M, et al. Comparison of drug survival rates for tumor necrosis factor antagonists in rheumatoid arthritis. Patient Pref Adher. 2013;7:719\u201327.","journal-title":"Patient Pref Adher"},{"key":"691_CR24","first-page":"4","volume":"78","author":"A Boonen","year":"2006","unstructured":"Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl. 2006;78:4\u201311.","journal-title":"J Rheumatol Suppl"},{"issue":"9570","key":"691_CR25","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379\u201390.","journal-title":"Lancet"},{"issue":"2","key":"691_CR26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00296-002-0237-4","volume":"23","author":"E Feldtkeller","year":"2003","unstructured":"Feldtkeller E, Khan MA, van der Heijde D, et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int. 2003;23(2):61\u20136.","journal-title":"Rheumatol Int"},{"issue":"6","key":"691_CR27","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896\u2013904.","journal-title":"Ann Rheum Dis"},{"key":"691_CR28","first-page":"24","volume":"78","author":"DO Clegg","year":"2006","unstructured":"Clegg DO, Clegg DO. Treatment of ankylosing spondylitis. J Rheumatol Suppl. 2006;78:24\u201331.","journal-title":"J Rheumatol Suppl"},{"issue":"2","key":"691_CR29","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","volume":"68","author":"MM Ward","year":"2015","unstructured":"Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheum. 2015;68(2):282\u201398.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"691_CR30","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/rheumatology\/35.1.60","volume":"35","author":"E Klerk De","year":"1996","unstructured":"De Klerk E, Van der Linden S. Compliance monitoring of NSAID drug therapy in ankylosing spondylitis, experiences with an electronic monitoring device. Rheumatology. 1996;35(1):60\u20135.","journal-title":"Rheumatology"},{"issue":"3","key":"691_CR31","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/ar1941","volume":"8","author":"L Carmona","year":"2006","unstructured":"Carmona L, G\u00f3mez-Reino JJ. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther. 2006;8(3):R72.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"691_CR32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/art.23333","volume":"59","author":"MS Heiberg","year":"2008","unstructured":"Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of anti-tumor necrosis factor \u03b1 drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Care Res. 2008;59(2):234\u201340.","journal-title":"Arthritis Care Res"},{"issue":"6","key":"691_CR33","first-page":"958","volume":"27","author":"K Pavelka","year":"2009","unstructured":"Pavelka K, Forejtova S, Stolfa J, et al. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clin Exp Rheumatol. 2009;27(6):958\u201363.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"691_CR34","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s10067-013-2221-7","volume":"32","author":"P Arturi","year":"2013","unstructured":"Arturi P, Schneeberger EE, Sommerfleck F, et al. Adherence to treatment in patients with ankylosing spondylitis. Clin Rheumatol. 2013;32(7):1007\u201315.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"691_CR35","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3899\/jrheum.150414","volume":"43","author":"A-L Betegnie","year":"2016","unstructured":"Betegnie A-L, Gauchet A, Lehmann A, et al. Why do patients with chronic inflammatory rheumatic diseases discontinue their biologics? An assessment of patients\u2019 adherence using a self-report questionnaire. J Rheumatol. 2016;43(4):724\u201330.","journal-title":"J Rheumatol"},{"issue":"1","key":"691_CR36","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00296-015-3348-4","volume":"36","author":"R Lyu","year":"2016","unstructured":"Lyu R, Govoni M, Ding Q, et al. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany. Rheumatol Int. 2016;36(1):143\u201353.","journal-title":"Rheumatol Int"},{"issue":"4","key":"691_CR37","first-page":"451","volume":"46","author":"SK Rai","year":"2016","unstructured":"Rai SK, Avina-Zubieta JA, McCormick N, et al. The rising prevalence and incidence of gout in British Columbia, Canada: population-based trends from 2000 to 2012. Semin Arthritis Rheum. 2016;46(4):451\u20136.","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl 2","key":"691_CR38","doi-asserted-by":"crossref","first-page":"ii9","DOI":"10.1093\/rheumatology\/kep087","volume":"48","author":"F Perez-Ruiz","year":"2009","unstructured":"Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology. 2009;48(Suppl 2):ii9\u2013ii14.","journal-title":"Rheumatology"},{"issue":"7","key":"691_CR39","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","volume":"125","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012;125(7):679\u201387.e1.","journal-title":"Am J Med"},{"issue":"10","key":"691_CR40","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD, et al. American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64(10):1447\u201361.","journal-title":"Arthritis Care Res"},{"issue":"10","key":"691_CR41","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"691_CR42","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s10067-014-2823-8","volume":"35","author":"B McGowan","year":"2016","unstructured":"McGowan B, Bennett K, Silke C, et al. Adherence and persistence to urate-lowering therapies in the Irish setting. Clin Rheumatol. 2016;35(3):715\u201321.","journal-title":"Clin Rheumatol"},{"issue":"11","key":"691_CR43","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1136\/annrheumdis-2012-201687","volume":"71","author":"M Doherty","year":"2012","unstructured":"Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis. 2012;71(11):1765\u201370.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"691_CR44","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/kes431","volume":"52","author":"G Zandman-Goddard","year":"2013","unstructured":"Zandman-Goddard G, Amital H, Shamrayevsky N, et al. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel. Rheumatology. 2013;52(6):1126\u201331.","journal-title":"Rheumatology"},{"issue":"6","key":"691_CR45","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11926-007-0073-3","volume":"9","author":"AR Setty","year":"2007","unstructured":"Setty AR, Choi HK. Psoriatic arthritis epidemiology. Curr Rheumatol Rep. 2007;9(6):449\u201354.","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"691_CR46","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(2):ii14\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"691_CR47","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499\u2013510.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"691_CR48","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/ar2670","volume":"11","author":"AA Saad","year":"2009","unstructured":"Saad AA, Ashcroft DM, Watson KD, et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther. 2009;11(2):R52.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"691_CR49","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s12325-012-0039-3","volume":"29","author":"B Chastek","year":"2012","unstructured":"Chastek B, Fox KM, Watson C, et al. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan. Adv Ther. 2012;29(8):691\u20137.","journal-title":"Adv Ther"},{"key":"691_CR50","volume-title":"Kelley\u2019s textbook of rheumatology: expert consult premium edition","author":"GS Firestein","year":"2012","unstructured":"Firestein GS, Budd RC, Gabriel SE, et al. Kelley\u2019s textbook of rheumatology: expert consult premium edition. 9th ed. Philadelphia: Saunders; 2012. 2292 p.","edition":"9"},{"issue":"4","key":"691_CR51","first-page":"330","volume":"6","author":"M Cojocaru","year":"2011","unstructured":"Cojocaru M, Cojocaru IM, Silosi I, et al. Manifestations of systemic lupus erythematosus. Maedica (Buchar). 2011;6(4):330\u20136.","journal-title":"Maedica (Buchar)"},{"key":"691_CR52","doi-asserted-by":"crossref","unstructured":"Klippel JH, Stone JH, White PH. Primer on the rheumatic diseases. Springer Science & Business Media; 2008. 703 p.","DOI":"10.1007\/978-0-387-68566-3"},{"issue":"3","key":"691_CR53","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/art.37795","volume":"65","author":"CH Feldman","year":"2013","unstructured":"Feldman CH, Hiraki LT, Liu J, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum. 2013;65(3):753\u201363.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"691_CR54","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","volume":"71","author":"GK Bertsias","year":"2012","unstructured":"Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association\u2013European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771\u201382.","journal-title":"Ann Rheum Dis"},{"key":"691_CR55","first-page":"601","volume-title":"Dubois\u2019 lupus erythematosus and related syndromes","author":"JA Avi\u00f1a-Zubieta","year":"2012","unstructured":"Avi\u00f1a-Zubieta JA, Esdaile JM. Chapter 49. Antimalarial medications. In: Wallace D, Hahn BH, editors. Dubois\u2019 lupus erythematosus and related syndromes. 8th ed. Philadelphia: Elsevier Saunders; 2012. p. 601\u20138.","edition":"8th"},{"issue":"5","key":"691_CR56","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.semarthrit.2008.01.011","volume":"38","author":"LR Harrold","year":"2009","unstructured":"Harrold LR, Andrade SE. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum. 2009;38(5):396\u2013402.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"691_CR57","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s10067-007-0816-6","volume":"27","author":"A Garcia-Gonzalez","year":"2008","unstructured":"Garcia-Gonzalez A, Richardson M, Garcia Popa-Lisseanu M, et al. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol. 2008;27(7):883\u20139.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"691_CR58","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/RHU.0b013e31817a242a","volume":"14","author":"S Koneru","year":"2008","unstructured":"Koneru S, Kocharla L, Higgins GC, et al. Adherence to medications in systemic lupus erythematosus. J Clin Rheumatol. 2008;14(4):195\u2013201.","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"691_CR59","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/0961203310383736","volume":"20","author":"M Oliveira-Santos","year":"2011","unstructured":"Oliveira-Santos M, Verani JF, Klumb EM, et al. Evaluation of adherence to drug treatment in patients with systemic lupus erythematosus in Brazil. Lupus. 2011;20(3):320\u20139.","journal-title":"Lupus"},{"key":"691_CR60","doi-asserted-by":"crossref","unstructured":"Abdul-Sattar AB, Abou El Magd SA. Determinants of medication non-adherence in Egyptian patients with systemic lupus erythematosus: Sharkia Governorate. Rheumatol Int. 2015;35(6):1045\u201351.","DOI":"10.1007\/s00296-014-3182-0"},{"key":"691_CR61","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2147\/PPA.S79451","volume":"10","author":"LR Prudente","year":"2016","unstructured":"Prudente LR, Diniz Jde S, Ferreira TX, et al. Medication adherence in patients in treatment for rheumatoid arthritis and systemic lupus erythematosus in a university hospital in Brazil. Patient Pref Adher. 2016;10:863\u201370.","journal-title":"Patient Pref Adher"},{"issue":"12","key":"691_CR62","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/art.1780341205","volume":"34","author":"CE Dugowson","year":"1991","unstructured":"Dugowson CE, Koepsell TD, Voigt LF, et al. Rheumatoid arthritis in women. Incidence rates in group health cooperative, Seattle, Washington, 1987-1989. Arthritis Rheum. 1991;34(12):1502\u20137.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"691_CR63","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3899\/jrheum.110207","volume":"39","author":"VP Bykerk","year":"2012","unstructured":"Bykerk VP, Akhavan P, Hazlewood GS, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol. 2012;39(8):1559\u201382.","journal-title":"J Rheumatol"},{"issue":"5","key":"691_CR64","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","volume":"64","author":"JA Singh","year":"2012","unstructured":"Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5):625\u201339.","journal-title":"Arthritis Care Res"},{"issue":"12","key":"691_CR65","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1002\/art.27691","volume":"62","author":"V Bykerk","year":"2010","unstructured":"Bykerk V, Emery P. Delay in receiving rheumatology care leads to long-term harm. Arthritis Rheum. 2010;62(12):3519\u201321.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"691_CR66","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","volume":"52","author":"YP Goekoop-Ruiterman","year":"2005","unstructured":"Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381\u201390.","journal-title":"Arthritis Rheum"},{"issue":"9664","key":"691_CR67","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(09)60008-8","volume":"373","author":"L Klareskog","year":"2009","unstructured":"Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2009;373(9664):659\u201372.","journal-title":"Lancet"},{"issue":"6","key":"691_CR68","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0002-9343(01)00872-5","volume":"111","author":"LR Lard","year":"2001","unstructured":"Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med. 2001;111(6):446\u201351.","journal-title":"Am J Med"},{"issue":"4","key":"691_CR69","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/art.10135","volume":"46","author":"T Mottonen","year":"2002","unstructured":"Mottonen T, Hannonen P, Korpela M, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum. 2002;46(4):894\u20138.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"691_CR70","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/art.20712","volume":"52","author":"MA Quinn","year":"2005","unstructured":"Quinn MA, Conaghan PG, O\u2019Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(1):27\u201335.","journal-title":"Arthritis Rheum"},{"key":"691_CR71","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2217\/ijr.10.15","volume":"5","author":"S Achaval de","year":"2010","unstructured":"de Achaval S, Suarez-Almazor ME. Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Clin Rheumatol. 2010;5:313\u201326.","journal-title":"Int J Clin Rheumatol"},{"issue":"7","key":"691_CR72","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.clinthera.2011.06.001","volume":"33","author":"MA Blum","year":"2011","unstructured":"Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther. 2011;33(7):901\u201313.","journal-title":"Clin Ther"},{"issue":"7","key":"691_CR73","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0149-2918(08)80063-X","volume":"30","author":"B Tang","year":"2008","unstructured":"Tang B, Rahman M, Waters HC, et al. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther. 2008;30(7):1375\u201384.","journal-title":"Clin Ther"},{"issue":"6","key":"691_CR74","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1185\/03007990902896386","volume":"25","author":"BJ Borah","year":"2009","unstructured":"Borah BJ, Huang X, Zarotsky V, et al. Trends in RA patients\u2019 adherence to subcutaneous anti-TNF therapies and costs. Curr Med Res Opin. 2009;25(6):1365\u201377.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"691_CR75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171070","volume":"12","author":"A Pasma","year":"2017","unstructured":"Pasma A, Schenk C, Timman R, et al. Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment? PLoS One. 2017;12(2):e0171070.","journal-title":"PLoS One"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-017-0691-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-017-0691-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-017-0691-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T19:44:59Z","timestamp":1750880699000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-017-0691-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,18]]},"references-count":75,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["691"],"URL":"https:\/\/doi.org\/10.1007\/s11926-017-0691-3","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,18]]},"article-number":"66"}}